Skip to main content
AmigoFish

How Eli Lilly's biotech collaboration model is rewriting early-stage innovation

From Beyond Biotech - the podcast from Labiotech · · 35 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Today, we're joined by Thomas Hopkins, Vice President and Head of ExploR&D at Eli Lilly. With a background as a physician-scientist in oncology, Thomas has spent his career bridging bold discovery science with rigorous development, first in academia and clinical practice, then at Lilly since 2015.

Lilly ExploR&D (https://explornd.lilly.com) represents new thinking in the pharma-biotech collaboration model: a shared-risk, deep scientific partnership designed specifically for early-stage biotechs. It provides full-stack R&D capabilities helping companies overcome the toughest hurdles in moving from molecule creation to clinical proof-of-concept, all while staying lean in a challenging funding environment.

In this episode, Thomas dives into his journey shaping ExploR&D, how the program works in practice, current priorities in modalities and therapeutic areas, and offers some practical advice for biotechs seeking to partner with Eli Lilly.

01:30 — Meet Tom Hopkins

05:11 — What makes ExploR&D biotech-friendly

07:46 — How collaborations work in practice

09:40 — Shared risk models

14:25 — Engaging bold science early

28:16 — Success stories and advice for biotechs

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast)

Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast)

To dive deeper into the topic:

- Eli Lilly’s strategy in motion: Beyond diabetes and obesity (https://www.labiotech.eu/in-depth/eli-lilly-pipeline-strategy/)

- Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? (https://www.labiotech.eu/trends-news/eli-lilly-partnerships-surge-2025/)

- What to look for in a biotech incubator (https://www.labiotech.eu/expert-advice/biotech-incubator/)

Back to Beyond Biotech - the podcast from Labiotech · Report a problem